PRI: Drug Manufacturers Make Below Average Returns Relative to Risk While Insurers See Excessive Profit

A study published this week by the Pacific Research Institute found that the return on capital for health insurers and PBMs is four times higher than it is for drug manufacturers. Yet, so often, we’re told biopharmaceutical companies are the ones earning excessive returns.